









Markets
/
Stocks
/
nasdaq-axsm
/

Axsome Therapeutics Inc

AXSM

133.950USD

-0.980-0.73%

Market hours （ET）Quotes delayed by 15 min

6.74BMarket Cap

LossP/E TTM



Axsome Therapeutics Inc

133.950

-0.980-0.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Axsome Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Axsome Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

17 / 159

Overall Ranking

57 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

178.947

Target Price

+31.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Axsome Therapeutics Inc Highlights

StrengthsRisks

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 670.81% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 385.69M.

Undervalued

The company’s latest PE is -28.89, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 38.81M shares, decreasing 7.78% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 107.29K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.12, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 150.04M, representing a year-over-year increase of 72.13%, while its net profit experienced a year-over-year increase of 39.54%.

Score

Industry at a Glance

Previous score

8.12

Change



Financials

6.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.76

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Axsome Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.11, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -28.89, which is -64.74% below the recent high of -10.19 and 0.00% above the recent low of -28.89.

Score

Industry at a Glance

Previous score

7.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.70, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Axsome Therapeutics Inc is 185.00, with a high of 205.00 and a low of 148.00.

Score

Industry at a Glance

Previous score

8.70

Change

Support & Resistance

No Data

Analyst Rating

Based on 20 analysts

Buy

Current Rating

179.053

Target Price

+32.70%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Axsome Therapeutics Inc

AXSM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 9.24, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 142.75 and the support level at 122.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.757

Buy

RSI(14)

64.443

Neutral

STOCH(KDJ)(9,3,3)

81.173

Overbought

ATR(14)

5.436

Low Volatility

CCI(14)

87.319

Neutral

Williams %R

20.348

Buy

TRIX(12,20)

0.484

Sell

StochRSI(14)

37.394

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

134.430

Sell

MA10

132.667

Buy

MA20

128.989

Buy

MA50

123.742

Buy

MA100

115.173

Buy

MA200

114.142

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 77.77%, representing a quarter-over-quarter decrease of 16.49%. The largest institutional shareholder is The Vanguard, holding a total of 3.94M shares, representing 7.89% of shares outstanding, with 1.44% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Antecip Capital, L.L.C.

7.34M

The Vanguard Group, Inc.

Star Investors

3.94M

+1.75%

BlackRock Institutional Trust Company, N.A.

3.14M

+5.86%

BVF Partners L.P.

1.69M

RTW Investments L.P.

1.52M

-48.10%

Macquarie Investment Management

1.14M

+16.54%

Geode Capital Management, L.L.C.

989.45K

+5.84%

State Street Investment Management (US)

958.50K

+5.79%

Fairmount Funds Management LLC

815.18K

Deep Track Capital LP

801.37K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 8.28, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.